Q3 2025 · 13F-HR
Affinity Asset Advisors, LLCholdings as filed
Filed 2025-11-13 · accession 0001999371-25-017685
$1.15B
Reported value
96
Positions
2025-09-30
Period end
The Brief · Affinity Asset Advisors, LLC · Q3 2025
AI · grounded in 13F
Affinity Asset Advisors, LLC established a new position in INSM valued at $94.3M. The fund also initiated new stakes in VRNA for $66.7M and SPY for $56.3M. Other new additions include XENE at $56.2M and MDGL at $52.7M. Total assets under management stand at $1.15B across 93 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 925050106 | VRNA | VERONA PHARMA PLC | $66.7M | 5.81% | 625,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $64.8M | 5.65% | 450,000 | Common | SOLE |
| 78462F103 | SPY | SPDR S&P 500 ETF TR | $56.3M | 4.90% | 84,490 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $56.2M | 4.90% | 1,400,000 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $52.7M | 4.59% | 115,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $46.6M | 4.06% | 1,173,426 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $41.0M | 3.58% | 500,000 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $37.5M | 3.27% | 1,250,000 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $33.2M | 2.90% | 384,417 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $30.6M | 2.66% | 360,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $29.5M | 2.57% | 205,000 | CALL | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $28.4M | 2.48% | 750,000 | Common | SOLE |
| 881624209 | TEVA | TEVA PHARMACEUTICAL INDS LTD | $28.3M | 2.46% | 1,400,000 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $26.9M | 2.34% | 285,769 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $26.8M | 2.34% | 1,107,162 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $25.7M | 2.24% | 3,870,527 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $25.6M | 2.23% | 2,800,000 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $23.8M | 2.07% | 1,419,299 | Common | SOLE |
| 76200L309 | RZLT | REZOLUTE INC | $19.7M | 1.72% | 2,100,000 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $19.2M | 1.68% | 350,000 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $18.4M | 1.61% | 959,180 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $17.5M | 1.53% | 300,000 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $15.4M | 1.34% | 2,100,000 | Common | SOLE |
| 74366e102 | — | PROTAGONIST THERAPEUTICS INC | $14.7M | 1.28% | 220,600 | Common | SOLE |
| 30161Q104 | EXEL | EXELIXIS INC | $14.5M | 1.26% | 350,000 | PUT | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $13.5M | 1.18% | 200,000 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $12.8M | 1.11% | 1,006,217 | Common | SOLE |
| G31249108 | ESTA | ESTABLISHMENT LABS HLDGS INC | $12.7M | 1.11% | 310,000 | Common | SOLE |
| 48576UAA4 | KPTI 3 10/15/25 | KARYOPHARM THERAPEUTICS INC | $12.5M | 1.09% | 15,250,000 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $12.2M | 1.06% | 3,924,415 | Common | SOLE |
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $12.1M | 1.05% | 800,000 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $11.9M | 1.04% | 500,000 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $10.3M | 0.90% | 262,100 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $9.8M | 0.85% | 3,000,000 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $9.3M | 0.81% | 4,285,787 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $8.9M | 0.78% | 967,620 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $8.8M | 0.77% | 303,330 | Common | SOLE |
| 29337e102 | — | ENLIVEN THERAPEUTICS INC | $8.2M | 0.71% | 400,000 | Common | SOLE |
| 89422GAA5 | TVTX 2.25 03/01/29 | TRAVERE THERAPEUTICS INC | $7.9M | 0.69% | 7,000,000 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $7.8M | 0.68% | 275,000 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $7.8M | 0.68% | 300,000 | Common | SOLE |
| N71542109 | PRQR | PROQR THRAPEUTICS N V | $7.7M | 0.67% | 3,600,000 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $7.4M | 0.65% | 125,000 | Common | SOLE |
| 86627T108 | SMMT | SUMMIT THERAPEUTICS INC | $7.2M | 0.63% | 350,000 | PUT | SOLE |
| 00972D105 | AKBA | AKEBIA THERAPEUTICS INC | $6.7M | 0.58% | 2,450,000 | Common | SOLE |
| 61023L207 | MNPR | MONOPAR THERAPEUTICS INC | $6.5M | 0.57% | 79,483 | Common | SOLE |
| 30161Q104 | EXEL | EXELIXIS INC | $6.2M | 0.54% | 150,000 | CALL | SOLE |
| G9TY5A101 | ZURA | ZURA BIO LTD | $5.5M | 0.48% | 1,274,351 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $5.4M | 0.47% | 250,000 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $5.4M | 0.47% | 1,500,000 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $5.2M | 0.45% | 300,000 | CALL | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $4.8M | 0.42% | 300,000 | Common | SOLE |
| 682143AK8 | OMER 9.5 06/15/29 | OMEROS CORP | $4.7M | 0.41% | 5,525,000 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $4.7M | 0.41% | 100,000 | Common | SOLE |
| 682143102 | OMER | OMEROS CORP | $4.6M | 0.40% | 1,133,900 | PUT | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $4.5M | 0.39% | 125,000 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $4.2M | 0.37% | 245,000 | Common | SOLE |
| 15102KAA8 | CELC 2.75 08/01/31 | CELCUITY INC | $4.0M | 0.35% | 3,000,000 | Common | SOLE |
| G70077105 | PCSC | PERCEPTIVE CAP SOLUTIONS COR | $3.8M | 0.33% | 350,000 | Common | SOLE |
| 457730109 | INSP | INSPIRE MED SYS INC | $3.7M | 0.32% | 50,000 | Common | SOLE |
| 690469101 | OVID | OVID THERAPEUTICS INC | $3.4M | 0.30% | 2,650,000 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $3.4M | 0.29% | 65,000 | Common | SOLE |
| G50871105 | JAZZ | JAZZ PHARMACEUTICALS PLC | $3.3M | 0.29% | 25,000 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $3.1M | 0.27% | 75,000 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $2.9M | 0.25% | 165,000 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $2.9M | 0.25% | 1,750,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $2.8M | 0.24% | 239,000 | Common | SOLE |
| G6717R120 | OACCU | OAKTREE ACQUISITION CORP III | $2.7M | 0.23% | 250,000 | Common | SOLE |
| 28658R106 | CLYM | CLIMB BIO INC | $2.6M | 0.23% | 1,300,000 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $2.4M | 0.21% | 250,000 | CALL | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $2.4M | 0.21% | 250,000 | Common | SOLE |
| 786700104 | SGMT | SAGIMET BIOSCIENCES INC | $2.4M | 0.21% | 350,000 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $2.2M | 0.19% | 300,000 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP DEL | $2.1M | 0.18% | 5,000 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $2.1M | 0.18% | 1,500,000 | Common | SOLE |
| 03675P102 | AVR | ANTERIS TECHNOLOGIES GLOBAL | $2.0M | 0.18% | 450,000 | Common | SOLE |
| 68572M106 | OBIO | ORCHESTRA BIOMED HLDGS INC | $1.8M | 0.16% | 727,272 | Common | SOLE |
| 29842P105 | EPRX | EUPRAXIA PHARMACEUTICALS INC | $1.8M | 0.15% | 300,000 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $1.6M | 0.14% | 263,817 | Common | SOLE |
| 002120202 | ATYR | ATYR PHARMA INC | $1.5M | 0.13% | 2,100,000 | PUT | SOLE |
| 59935V107 | MIST | MILESTONE PHARMACEUTICALS IN | $1.3M | 0.12% | 666,666 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $1.1M | 0.10% | 200,000 | Common | SOLE |
| 65343E207 | NXTC | NEXTCURE INC | $1.1M | 0.10% | 191,882 | Common | SOLE |
| 48576U205 | KPTI | KARYOPHARM THERAPEUTICS INC | $1.0M | 0.09% | 157,600 | CALL | SOLE |
| 46489V302 | CATX | PERSPECTIVE THERAPEUTICS INC | $1.0M | 0.09% | 300,000 | Common | SOLE |
| 03879J100 | ABUS | ARBUTUS BIOPHARMA CORP | $960,210 | 0.08% | 211,500 | CALL | SOLE |
| 869367102 | STRO | SUTRO BIOPHARMA INC | $653,664 | 0.06% | 752,722 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $563,686 | 0.05% | 65,317 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $525,910 | 0.05% | 77,000 | Common | SOLE |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $390,090 | 0.03% | 402,653 | Common | SOLE |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $352,000 | 0.03% | 200,000 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $213,996 | 0.02% | 17,998 | Common | SOLE |
| 00534B100 | ADGM | ADAGIO MED HLDGS INC | $155,200 | 0.01% | 80,000 | Common | SOLE |
| 746964105 | QTTB | Q32 BIO INC | $54,998 | 0.00% | 27,777 | Common | SOLE |
| 82835W108 | SPRY | ARS PHARMACEUTICALS INC | $25,125 | 0.00% | 2,500 | Common | SOLE |
| 77313F114 | RCKTW | ROCKET PHARMACEUTICALS INC | $2,993 | 0.00% | 75,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.